I. MODIFIED AGREEMENTS
Biotech Co.*
(Country;
Symbol)		 Pharma Co.
(Country)		 Change from original
agreement		 Terms/Details (Date)
Memory
Pharmaceuticals
Corp. (MEMY)		 F. Hoffmann-La Roche Ltd. (Switzerland) Roche maintained its option to exclusively license MEM 3454 for treating neurological disorders The move followed Phase I work that resulted in a $2M milestone payment to Memory; Roche's option remains through Phase IIa trials (10/31)
II. TERMINATED AGREEMENTS
CV
Therapeutics
Inc. (CVTX)		 Solvay Pharmaceuticals Inc. CV is terminating the co-promotion agreement for Aceon The deal on the angiotensin-converting enzyme inhibitor was to have run through 2010; no payments are due under the termination (10/11)
Novacea Inc.(NOVC) Pierre Fabre Medicament SA (France) Novacea is returning to Pierre Fabre the U.S. and Canadian rights to oral vinorelbine Novacea licensed the cancer product in 2005; it was notified by the FDA that the development path would be longer than anticipated (11/1)
Notes:
# The information in the chart does not cover agreements between biotech companies or agricultural agreements.
* Private companies are indicated with an asterisk.
Unless otherwise noted, stock symbols listed are on the Nasdaq market.